# A-SEEDS Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/a-seeds-co

- Industry: Biotechnology
- Headquarters: Matsumoto-shi, Japan
- Website: www.a-seeds.co.jp/
- Total disclosed funding: $3M
- Latest round: Seed (Jan 4, 2024)
- Investors on record: 2

## About

Based in Matsumoto, Japan, and founded in 2020 by founder Yagyu Shigeki, A-SEEDS Co., Ltd. develops treatments for myeloid tumors and solid tumors using genetically modified immune cells called T cells. In January 2024, A-SEEDS Co., Ltd. raised JPY 440 million in seed funding from investors Hachijuni Investment and Green Core.
 
The company's primary focus is on overcoming challenges associated with CAR-T cell therapy for myeloid tumors and solid tumors. CAR-T cells produced through the PB method exhibit enhanced efficacy and sustained medicinal effects, attributed to the incorporation of "stem cell memory-like T cells. The proprietary PB method ensures the dominance of the CAR gene over memory T cells, preventing immune exhaustion and maximizing therapeutic efficacy. The company's advanced approach involves collaboration among physicians, researchers, safety testing departments, and clinical trial support units. The seamless integration facilitates the entire process, from basic development to non-clinical studies and clinical implementation, ensuring the delivery of non-viral genetically modified CAR-T cell therapy to patients in need.
 
The company plans to use the January 2024 funding to support US clinical trials for its therapeutic products.

## Funding rounds

- Seed, Jan 4, 2024, $3M — Hachijuni Investment, GREEN CORE

## Investors

- Hachijuni Investment (https://capitalatlas.ai/funds/hachijuni-investment) — Seed
- GREEN CORE — Seed